Drug holds promise as an alternative for sickle cell patients unable to tolerate standard treatment

November 17, 2003

(WASHINGTON, DC, November 17, 2003) -- A new drug may offer relief from sickle cell symptoms for patients who do not respond to the current standard of care, according to the December 1, 2003, issue of Blood, the official journal of the American Society of Hematology.

Sickle cell disease is an inherited disorder that causes patients' bone marrow to produce red blood cells with defective hemoglobin, which in turn causes red blood cells to become sickle-shaped. These irregular cells have difficulty passing through blood vessels, causing many symptoms, including excruciating pain episodes, recurrent pneumonias, and strokes.

"The standard treatment for sickle cell is the drug hydroxyurea. Hydroxyurea reactivates fetal hemoglobin, and increased fetal hemoglobin production is known to decrease the complications of sickle cell disease," said Yogen Saunthararajah, M.D., of the University of Illinois at Chicago, the lead author of the study. "Not all patients respond to treatment with hydroxyurea, prompting our team to investigate whether the antimetabolite drug decitabine could be used effectively in place of hydroxyurea for these patients."

To be eligible for this study, patients had to be 18 years of age or older and have sickle cell disease which was symptomatic. In addition, patients had to be either resistant to or intolerant of hydroxyurea. Between November 2001 and February 2002, eight patients were enrolled in the study. All patients had multiple clinically significant complications of sickle cell disease. Three patients had been on hydroxyurea for more than one year and failed to demonstrate a significant increase in fetal hemoglobin or decreased symptoms, and the remaining patients were forced to discontinue use of hydroxyurea due to complications. Decitabine was administered at relatively low doses of 0.2 mg/kg one to three times per week in two six-week cycles, with a two-week interval between cycles. The drug was administered subcutaneously in the thigh or upper arm.

Fetal hemoglobin levels and a number of other markers of disease activity improved in all patients, including those who had not responded to previous treatment with hydroxyurea. Patients tolerated decitabine well, with the only significant toxicity being neutropenia.

According to Dr. Saunthararajah, "Decitabine induces the production of fetal hemoglobin probably through a different mechanism than hydroxyurea. These results are exciting as patients who do not respond to hydroxyurea need alternative therapies that can increase the quality and quantity of their lives. Further studies with decitabine should be performed to demonstrate if this agent, administered over prolonged periods of time, can improve the quality of life for patients with sickle cell disease."

Richard T. Maziarz, M.D., Director of the Center for Hematologic Malignancies at Oregon Health & Science University, notes, "Great progress has been made in the care of patients with blood disorders over the past two decades by defining the molecular basis of their disease and developing therapies that circumvent these abnormalities. Unfortunately, there still are many disorders, like sickle cell disease, for which limited treatment options still remain. The observation that decitabine may provide a therapeutic option for those patients with sickle cell disease that are resistant or intolerant of hydroxyurea is noteworthy. However, further study is necessary to better define how or if this agent can be used with long term benefit and safety. Additionally, the effect of decitabine, using the dosage schedule examined, on the non-red cell blood counts suggests that further dose finding studies will be required."

In the United States, there are between 4,000 and 5,000 children born each year at risk for sickle cell disease. Across the world, it is estimated that more than 125,000 new cases are diagnosed annually.

This work was supported in part by SuperGen, Inc., the Illinois Department of Health/UIC Sickle Cell Center, the Sickle Cell Disease Association of America, and Public Health Services grants from the National Institutes of Health.

To receive a copy of the study or to arrange an interview with Yogen Saunthararajah, M.D., please contact Aislinn Raedy at (202) 776-0544 or araedy@hematology.org.
The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at www.bloodjournal.org.

American Society of Hematology

Related Sickle Cell Articles from Brightsurf:

New technology diagnoses sickle cell disease in record time
Researchers have developed a new way to diagnose diseases of the blood like sickle cell disease with sensitivity and precision and in only one minute.

Gut microbiome translates stress into sickle cell crises
A new study shows how chronic psychological stress leads to painful vessel-clogging episodes--the most common complication of sickle-cell disease (SCD) and a frequent cause of hospitalizations.

Cannabis shows potential for mitigating sickle cell disease pain
Cannabis appears to be a safe and potentially effective treatment for the chronic pain that afflicts people with sickle cell disease, according to a new clinical trial co-led by University of California, Irvine researcher Kalpna Gupta and Dr.

Researchers discover improved treatment for children with sickle cell anemia
A team of international researchers has learned that dose escalation of hydroxyurea treatment for children in Uganda with sickle cell anemia is more effective and has similar side effects than a lower fixed dose of the same drug.

Exploring mechanisms of resistance to HIV in people with sickle cell disease
A new analysis supports prior reports that people with sickle cell disease have lower rates of human immunodeficiency virus (HIV) infection, but follow-up cell studies did not reveal a mechanism to explain the reduced risk.

Computer model could help test new sickle cell drugs
A new computer model that captures the dynamics of the red blood cell sickling process could help in evaluating drugs for treating sickle cell disease.

Sickle cell drug showing promise in clinical trial
An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

Sickle cell disease needs more attention
Article signed by researchers affiliated with institutions in the US, UK, Ghana and Brazil highlights recent progress in diagnosis and treatment but warns that more screening of newborns is needed.

New genetic weapons challenge sickle cell disease
Researchers advancing gene-editing techniques to help patients with sickle cell disease discover an unexpected boost in fetal hemoglobin production, which mutes the effect of the disease.

Athletes with sickle cell traits are at more risk to collapse: here's why
A genetic variation known to affect sickle cell disease might be the reason why some college football players experience adverse clinical outcomes during periods of extreme physical exertion and others do not.

Read More: Sickle Cell News and Sickle Cell Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.